| abstract |
Provided herein are engineered, stabilized beta-coronavirus S2 proteins, such as engineered, stabilized MERS S2 proteins. In some aspects, the engineered S2 proteins exhibit enhanced antigenicity. Methods are also provided for use of the engineered S2 proteins as diagnostics, in screening platforms, and/or in vaccine compositions. |